NCT05319756View on ClinicalTrials.gov

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Abuse Potential
Interventions
DRUG

gabapentin 600 mg

Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl

DRUG

gabapentin 1200 mg

Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl

DRUG

gabapentin 600 mg and oxycodone HCl 20 mg

Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg

DRUG

gabapentin 1200 mg and oxycodone HCl 20 mg

Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg

DRUG

oxycodone HCl 20 mg

Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin

DRUG

placebo

Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl

Trial Locations (1)

080503

Hassman Research Institute, Marlton

All Listed Sponsors
lead

Viatris Specialty LLC

INDUSTRY